List of Excipients in Branded Drug INTEGRILIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme Corp	INTEGRILIN	eptifibatide	0085-1136	CITRIC ACID MONOHYDRATE
Merck Sharp & Dohme Corp	INTEGRILIN	eptifibatide	0085-1136	SODIUM HYDROXIDE
Merck Sharp & Dohme Corp	INTEGRILIN	eptifibatide	0085-1177	CITRIC ACID MONOHYDRATE
Merck Sharp & Dohme Corp	INTEGRILIN	eptifibatide	0085-1177	SODIUM HYDROXIDE

INTEGRILIN Excipient Strategy and Commercial Opportunities for Eptifibatide Injection

Last updated: August 2, 2026

Integrilin, the brand name for eptifibatide, is an intravenous glycoprotein IIb/IIIa platelet inhibitor used in acute coronary syndrome and percutaneous coronary intervention. Its excipient profile is deliberately simple: water for injection, citric acid, and sodium hydroxide. The commercial opportunity is therefore not a complex formulation platform. It is a low-cost injectable supply, packaging, stability, and hospital-procurement opportunity.

The main barriers are sterile manufacturing, peptide control, container-closure performance, validated dilution compatibility, and reliable supply. Conventional excipient differentiation has limited value unless it improves shelf life, reduces particulate risk, enables a more convenient presentation, or lowers manufacturing cost.

What is Integrilin and how is eptifibatide formulated?

Integrilin contains eptifibatide, a cyclic heptapeptide antagonist of the platelet glycoprotein IIb/IIIa receptor. The FDA-approved product is supplied as a sterile intravenous solution in two concentrations:

Product presentation	Eptifibatide concentration	Typical package
Bolus injection	2 mg/mL	10 mg/5 mL vial
Continuous infusion	0.75 mg/mL	75 mg/100 mL bag or bottle

The formulation uses:

• Eptifibatide
• Citric acid monohydrate
• Sodium hydroxide for pH adjustment
• Water for injection

The commercial product is preservative-free and intended for intravenous administration. The formulation pH is approximately 5.0 to 5.5, depending on the presentation and approved labeling [1].

Why the excipient system is strategically important

Eptifibatide is administered in acute-care settings where the product must be ready for immediate use. The excipient system must support:

• Peptide solubility
• Chemical stability during storage
• Low particulate burden
• Compatibility with glass vials, elastomeric closures, and infusion bags
• Safe dilution with commonly used intravenous fluids
• Reliable performance during prolonged hospital infusion

A simple formulation reduces inactive-ingredient risk and can support an abbreviated generic development program. It also limits opportunities for product differentiation based only on excipient selection.

What excipients protect the Integrilin formulation?

The formulation relies on pH control rather than a complex buffer or stabilizer system. Citric acid provides the acidic component, while sodium hydroxide adjusts the final pH. Water for injection is the vehicle.

Excipient function

Excipient	Primary function	Commercial relevance
Citric acid monohydrate	Acidic buffering and pH control	Supports peptide stability and reproducible formulation
Sodium hydroxide	pH adjustment	Controls final product pH and may affect degradation rate
Water for injection	Sterile vehicle	Determines solution quality, endotoxin control, and filling performance

No preservative is used. That choice is consistent with intravenous administration and reduces the risk of preservative-related toxicity, incompatibility, and regulatory review.

What excipients are not present?

The standard formulation does not rely on:

• Polysorbate surfactants
• Amino-acid stabilizers
• Sugars such as sucrose or trehalose
• Chelating agents such as EDTA
• Antimicrobial preservatives
• Organic cosolvents
• Lipid carriers
• Lyophilization bulking agents

This creates a relatively narrow excipient design space. A proposed reformulation would need to deliver a measurable advantage over the established aqueous solution.

How strong is the formulation patent estate for Integrilin?

The original Integrilin product was approved in the United States in 1998. Its primary regulatory exclusivity period expired long ago, and eptifibatide is now a mature injectable product with generic competition.

The commercially relevant protection is more likely to reside in manufacturing know-how, sterile-processing controls, analytical methods, and packaging execution than in active formulation patents.

Protection category	Current commercial relevance
Original active-ingredient patents	Generally historic for current US competition
New chemical entity exclusivity	Expired
Brand formulation patents	Limited practical impact for the basic aqueous formulation
Method-of-use patents	Potentially relevant only if an unexpired, listed claim remains
Manufacturing know-how	High practical relevance
Sterile filling and packaging controls	High practical relevance
Regulatory exclusivity	No current exclusivity barrier is expected for the legacy product

The FDA Orange Book should be checked for the current reference-listed product and any active listed patents before a launch decision. The basic commercial conclusion remains that generic entry is governed more by product quality, manufacturing economics, and supply reliability than by a major remaining patent barrier [2].

Are there Paragraph IV challenges for Integrilin?

Paragraph IV litigation is not the central risk profile for eptifibatide. The product is old, the active ingredient is chemically defined, and the generic market has developed around abbreviated new drug applications rather than a recent high-value patent dispute.

A generic sponsor could still submit a Paragraph IV certification against any listed patent. The practical probability of commercially significant litigation is low unless a current Orange Book listing covers a differentiated formulation, manufacturing process, or method of use.

What FDA regulatory pathway applies to eptifibatide injection?

A generic eptifibatide injection is generally pursued through an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The principal requirements are:

1. Pharmaceutical equivalence to the reference product.
2. Bioequivalence or an FDA-accepted waiver of conventional in vivo testing where applicable.
3. Matching strength and route of administration.
4. Sterility and endotoxin compliance.
5. Demonstrated stability through the proposed shelf life.
6. Container-closure integrity.
7. Adequate extractables and leachables data.
8. Labeling that is consistent with the reference product, subject to permitted generic changes.

Because the product is an injectable solution, the development burden differs from that of an oral product. The sponsor must establish that the formulation is qualitatively and quantitatively equivalent, or provide an FDA-accepted justification for any permitted difference in inactive ingredients.

Is eptifibatide a biologic requiring a biosimilar pathway?

No. Eptifibatide is a synthetic peptide drug, not a monoclonal antibody, recombinant protein, or other biological product regulated through the biosimilar pathway. A competitor generally does not need to file a 351(k) biosimilar application.

The relevant regulatory route is a generic-drug application, subject to the product-specific requirements for sterile injectable solutions.

What excipient strategies could create commercial value?

The strongest opportunities are operational rather than pharmacological.

1. Ready-to-use infusion presentations

A prefilled or ready-to-connect infusion presentation could reduce pharmacy preparation, dose-calculation errors, and handling steps. The commercial value would depend on:

• Compatibility with hospital infusion pumps
• Availability in standard bag volumes
• Low overfill
• Reliable container-closure integrity
• Resistance to accidental leakage
• Competitive unit economics

The principal regulatory question would be whether the presentation remains pharmaceutically equivalent or requires a different application pathway.

2. Extended in-use stability

An improved formulation could target longer stability after dilution or after opening the primary container. Hospitals value products that remain usable throughout a prolonged catheterization or coronary-care workflow.

Potential development approaches include:

• More precise pH control
• Lower oxygen exposure during filling
• Improved headspace management
• Low-binding container materials
• Better control of peptide aggregation and adsorption

Any claim of extended stability would require real-time and accelerated studies, dilution studies, photostability data, particulate testing, and compatibility assessment with administration sets.

3. Low-sorption packaging

Peptides can interact with glass, elastomers, tubing, and infusion bags. A low-sorption presentation could reduce delivered-dose variability, particularly during low-rate infusion or extended contact with administration components.

Candidate packaging strategies include:

• Coated elastomeric stoppers
• Low-binding polymer bags
• Optimized tubing compatibility
• Reduced extractables from closures
• Improved surface treatment of glass containers

This area has more practical value than adding a conventional stabilizer to an already simple aqueous formulation.

4. Concentrated presentations

A more concentrated product could reduce infusion volume and storage space. The development risk is substantial because higher concentration may increase:

• Aggregation
• Viscosity
• Adsorption
• Local concentration gradients during dilution
• Filling and dose-uniformity challenges

A concentrated product would also need to fit established clinical protocols. Hospitals may resist a concentration that requires changes to pump programming or medication-dispensing systems.

5. Alternative container formats

The standard market includes vials and larger infusion containers. Commercial differentiation could come from:

• Small-volume ready-to-use bags
• Dual-chamber systems
• Pharmacy bulk packages where permitted
• Unit-dose presentations
• Barcoded containers for automated medication systems

The most attractive format is likely a ready-to-use infusion product that minimizes compounding without materially increasing manufacturing cost.

What manufacturing and intellectual-property barriers affect eptifibatide?

Peptide manufacturing

Eptifibatide is a cyclic peptide. Its production requires control of:

• Peptide sequence and chain assembly
• Cyclization chemistry
• Disulfide or other ring-forming chemistry, as applicable to the specific structure
• Impurity profile
• Residual reagents
• Aggregates and degradants
• Assay and potency
• Sterility and endotoxins

The active ingredient is not as difficult to manufacture as a complex biologic, but it is more technically demanding than a conventional small-molecule injectable.

Analytical control

A robust analytical package should include:

• High-performance liquid chromatography assay
• Related substances and degradants
• Peptide identity testing
• Mass spectrometric confirmation where appropriate
• Subvisible and visible particulate testing
• pH and osmolality
• Sterility and bacterial endotoxins
• Container-closure integrity
• Stability-indicating methods

The analytical method package can become a meaningful barrier for smaller entrants, particularly when supply is outsourced.

Manufacturing know-how

The strongest defensible position may arise from process control rather than patent claims. Relevant know-how includes:

• Sequence-specific impurity removal
• Efficient cyclization
• Control of peptide aggregation
• Low-bioburden solution preparation
• Aseptic filling at commercial scale
• Container-closure selection
• Control of adsorption during storage and administration

This know-how can support licensing or contract-manufacturing revenue even when the active-ingredient patent estate is weak.

Which companies are positioned to compete in the eptifibatide market?

The market is populated by the original branded product and generic injectable suppliers. Generic competition has historically involved major injectable manufacturers and hospital-supply companies, including suppliers associated with Hospira, Pfizer, Teva, and other established generic-drug platforms, subject to changes in approvals and commercial availability.

The relevant competitive dimensions are:

Competitive factor	Importance
Unit price	High
Shortage resilience	High
FDA manufacturing history	High
Availability of both bolus and infusion strengths	High
Ready-to-use packaging	Medium to high
Hospital contract access	High
Shelf life	Medium
Excipient differentiation	Low to medium
Brand recognition	Low in a mature generic market

A supplier with reliable US sterile capacity can compete even without a differentiated formulation. A supplier with a superior ready-to-use format may obtain better hospital positioning, but the price premium must be justified by labor savings and reduced preparation risk.

What generic launch scenarios exist for Integrilin?

Scenario 1: Low-price conventional generic

This is the most straightforward strategy. The sponsor matches the reference formulation and competes on price, manufacturing reliability, and distribution.

Expected advantages:

• Lower development complexity
• Familiar hospital handling
• Easier formulary substitution
• Minimal clinical workflow change

The main risk is margin compression.

Scenario 2: Supply-reliability platform

A manufacturer can differentiate through redundant API sourcing, domestic sterile filling, extended inventory, and high service levels. This is commercially important because injectable hospital products are exposed to manufacturing interruptions and supply shortages.

Scenario 3: Ready-to-use product

A ready-to-use bag or unit-dose format could command a modest premium if it reduces pharmacy labor and preparation requirements. The product must align with hospital automation and medication-safety systems.

Scenario 4: Portfolio bundling

Eptifibatide could be bundled with other cardiovascular injectables, anticoagulants, thrombolytics, or catheterization-lab products. The value would come from contracting leverage and distribution efficiency rather than from the molecule itself.

How does Integrilin compare with competing antiplatelet products?

Eptifibatide competes with other glycoprotein IIb/IIIa inhibitors and with broader antiplatelet regimens.

Product	Active ingredient	Administration	Commercial positioning
Integrilin	Eptifibatide	IV bolus and infusion	Mature hospital injectable
Aggrastat	Tirofiban	IV infusion	Competing small-molecule GP IIb/IIIa inhibitor
ReoPro	Abciximab	IV	Antibody-based GP IIb/IIIa inhibitor with different manufacturing economics
Cangrelor	Cangrelor	IV	Alternative rapid-acting antiplatelet therapy
Clopidogrel	Clopidogrel	Oral	Lower-cost oral alternative in suitable patients
Ticagrelor	Ticagrelor	Oral	Oral P2Y12 inhibitor with broader chronic-use relevance

Eptifibatide's main commercial constraint is clinical substitution. Its opportunity is concentrated in settings where rapid, potent, intravenous platelet inhibition is required. Its excipient strategy cannot overcome a decline in clinical use caused by changes in PCI protocols or preference for alternative antiplatelet agents.

What revenue exposure does Integrilin create?

Current standalone revenue exposure is difficult to isolate because eptifibatide is sold through branded and generic hospital channels, and public companies often report it within broader injectable or cardiovascular portfolios.

The commercial opportunity is best assessed through market structure rather than legacy brand sales:

• Demand is hospital-based and procedure-linked.
• Volume depends on PCI and acute coronary syndrome treatment patterns.
• Pricing is exposed to generic competition.
• Shortages can create temporary pricing power.
• A single product has limited franchise value without portfolio integration.
• Ready-to-use packaging may improve gross margin more effectively than excipient reformulation.

For a potential entrant, the target market is a dependable niche injectable rather than a high-growth branded asset.

What licensing opportunities exist for eptifibatide?

Potential licensing structures include:

1. API supply agreements for synthetic eptifibatide.
2. Contract manufacturing of sterile finished product.
3. Regional commercialization rights.
4. Hospital portfolio bundling.
5. Co-development of ready-to-use infusion packaging.
6. Licensing of low-sorption container systems.
7. Technology transfer for analytical and aseptic manufacturing processes.

The most credible licensing asset is a validated sterile manufacturing platform with demonstrated stability and supply performance. A broad excipient patent covering a conventional citric-acid aqueous solution would be less likely to create durable value unless it solves a specific stability, packaging, or administration problem.

What is the geographic coverage of the commercial opportunity?

The United States is the most structured market because of FDA ANDA requirements, Orange Book substitution, and established hospital purchasing systems. Europe and other regulated markets offer opportunities through national marketing authorizations, centralized procurement, and generic injectable tenders.

Geographic priorities should be assessed by:

• Local approval requirements
• Hospital tender structure
• Availability of sterile manufacturing
• API import controls
• Reimbursement and procedure volume
• Local reference-product status
• Patent and supplementary protection certificate records
• Shortage history

The product is more attractive in jurisdictions with high PCI volume and recurring hospital demand. Low-volume markets may not support dedicated sterile manufacturing unless the product is bundled with a broader injectable portfolio.

Key Takeaways

• Integrilin is eptifibatide, a mature synthetic peptide injectable approved in the United States in 1998.
• The formulation is simple and contains citric acid, sodium hydroxide, and water for injection.
• Conventional excipient differentiation has limited commercial value.
• The strongest opportunities involve ready-to-use packaging, low-sorption containers, extended in-use stability, and supply reliability.
• Eptifibatide is regulated as a generic drug, not through the biosimilar pathway.
• The original regulatory exclusivity period has expired, and the current competitive environment is primarily generic.
• The practical barriers are sterile manufacturing, peptide impurity control, analytical validation, packaging compatibility, and hospital contracting.
• A commercial entrant should prioritize product availability and workflow efficiency over complex reformulation.
• Licensing value is more likely to reside in manufacturing and packaging technology than in a basic aqueous excipient composition.

FAQs

Can eptifibatide be reformulated as a lyophilized product?

Yes, but the commercial case is weak unless lyophilization materially improves shelf life, transport, or global distribution. Reconstitution adds handling steps and may reduce the convenience of the current ready-to-use solution.

Would a preservative improve the commercial value of Integrilin?

Unlikely. Intravenous hospital products generally favor preservative-free presentations. A preservative could create additional safety, compatibility, and regulatory burdens without solving a clear commercial problem.

Is a prefilled syringe a realistic eptifibatide opportunity?

A prefilled syringe may be suitable for the bolus presentation if dose volume, syringe compatibility, peptide stability, and hospital workflow support it. The infusion presentation is more naturally suited to a ready-to-use bag or bottle.

Can a new eptifibatide formulation obtain three-year FDA exclusivity?

A qualifying new formulation may be eligible for three-year exclusivity if it is approved through a supplement or application that includes new clinical investigations essential to approval. The exclusivity would protect the approved change, not necessarily block all conventional generic eptifibatide products.

What is the highest-value excipient research question for eptifibatide?

The highest-value question is whether container and administration-set interactions reduce delivered peptide concentration or increase aggregation during the full period of clinical use. A validated low-sorption packaging system would have greater commercial relevance than adding a conventional stabilizer.

References

1. U.S. Food and Drug Administration. (2007). Integrilin (eptifibatide) injection prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.

4. U.S. Food and Drug Administration. (2014). Eptifibatide injection product information and abbreviated new drug application records. FDA.

5. The United States Pharmacopeia. (2024). General chapter <797>: Pharmaceutical compounding - sterile preparations. USP.